Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Items 101–200 of 1,000
How we treat metastatic colorectal cancer
Falco, V. D., Napolitano, S., Roselló, S., Huerta, M., Cervantes, A. M. R., Ciardiello, F., & Troiani, T. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000813 · Cited by 105
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 99
Mauri, G., Pizzutilo, E. G., Amatu, A., Bencardino, K., Palmeri, L., Bonazzina, E. F., Tosi, F., Carlo Stella, G., Burrafato, G., Scaglione, F., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.006 · Cited by 90
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone
Glimelius, B. L. G., Stintzing, S., Marshall, J. L., Yoshino, T., & de Gramont, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102218 · Cited by 112
Self-citationvan de Haar, J., Ma, X., Ooft, S. N., van der Helm, P. W., Hoes, L. R., Mainardi, S., Pinato, D. J., Sun, K., Salvatore, L., Tortora, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02240-8 · Cited by 83
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Meijerink, M. R., Ruarus, A. H., Vroomen, L. G. P. H., Puijk, R. S., Geboers, B., Nieuwenhuizen, S., van den Bemd, B. A. T., Nielsen, K., de Vries, J. J. J., van Lienden, K. P., et al. (2021) · Radiology · doi:10.1148/radiol.2021203089 · Cited by 89
Yoshino, T., Cervantes, A. M. R., Bando, H., Martinelli, E., Oki, E., Xu, R., Mulansari, N. A., Babu, K. G., Lee, M. A., Tan, C., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101558 · Cited by 105
Self-citationTrifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer
Burness, C. B., & Duggan, S. T. (2016) · Drugs · doi:10.1007/s40265-016-0633-9 · Cited by 86
Parseghian, C. M., Sun, R., Woods, M. N., Napolitano, S., Lee, H. M., Alshenaifi, J. Y., Willis, J. A., Nunez, S., Raghav, K. P. S., Morris, V. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01423 · Cited by 91
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice
Bekaii‐Saab, T., Kim, R. D., Kim, T. W., O’Connor, J. M., Strickler, J. H., Malka, D., Bianchi, A. S., Bi, F., Yamaguchi, K., Yoshino, T., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.11.002 · Cited by 88
Self-citationKasi, P. M., & Grothey, A. (2018) · Drugs · doi:10.1007/s40265-018-0909-3 · Cited by 80
Systemic treatment for metastatic colorectal cancer in the era of precision medicine
Sandhu, J. S., Lavingia, V. K., & Fakih, M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25421 · Cited by 86
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
Myint, Z. W., & Goel, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0454-7 · Cited by 81
Arora, S. P., Hurez, V. J., Nawrocki, S. T., Goros, M., Michalek, J. E., Sarantopoulos, J., Curiel, T. J., & Mahalingam, D. (2016) · Oncotarget · doi:10.18632/oncotarget.10824 · Cited by 82
Dynamic roles of inflammasomes in inflammatory tumor microenvironment
Jang, J., Kim, D., & Surh, Y. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00154-7 · Cited by 86
Cremolini, C., Chalabi, M., Élez, E., Fassan, M., Gelli, M., Goèré, D., Modest, D. P., Viladot, C. M., Osterlund, P. J., Ricke, J., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.03.005 · Cited by 119
Self-citationDueland, S., Foss, A., Solheim, J. M., Hagness, M., & Line, P. (2018) · British journal of surgery · doi:10.1002/bjs.10769 · Cited by 83
Mauri, G., Gori, V., Bonazzina, E. F., Amatu, A., Tosi, F., Bencardino, K. B., Ruggieri, L., Patelli, G., Arena, S., Bardelli, A., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102112 · Cited by 87
Monge, C., Xie, C., Myojin, Y., Coffman, K., Hrones, D. M., Wang, S., Hernandez, J. M., Wood, B. J., Levy, E. B., Juburi, I., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005640 · Cited by 75
Ducreux, M. P., Pétersen, L. N., Öhler, L., Bergamo, F., Metges, J., de Groot, J. W., Wang, J., de Paredes, B. G., Dochy, E., Fiala-Buskies, S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.015 · Cited by 80
Self-citationKuang, C., Park, Y., Augustin, R. C., Lin, Y., Hartman, D. J., Seigh, L., Pai, R. K., Sun, W., Bahary, N., Ohr, J. P., et al. (2022) · Clinical Epigenetics · doi:10.1186/s13148-021-01226-y · Cited by 79
Miranda, V. D. C., Braghiroli, M. I., Faria, L. D. B. B., Bariani, G. M., Alex, A. K., Neto, J. E. B., Capareli, F. C., Sabbaga, J., dos Santos, J. F. L., Hoff, P. M., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.04.011 · Cited by 85
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
Arnold, D., Prager, G. W., Quintela, A., Stein, A., Vera, S. R. M., Mounedji, N., & Taïeb, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy038 · Cited by 76
Masuishi, T., Taniguchi, H., Hamauchi, S., Komori, A., Kito, Y., Narita, Y., Tsushima, T., Ishihara, M., Todaka, A., Tanaka, T., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.019 · Cited by 75
Self-citationKasi, P. M., Kotani, D., Cecchini, M., Shitara, K., Ohtsu, A., Ramanathan, R. K., Hochster, H. S., Grothey, A., & Yoshino, T. (2016) · BMC Cancer · doi:10.1186/s12885-016-2491-y · Cited by 75
Self-citationCiombor, K. K., & Bekaii‐Saab, T. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0203 · Cited by 79
Abrahão, A. B. K., Ko, Y., Berry, S. R., & Chan, K. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.016 · Cited by 74
Identification of 1,2,4-triazoles as new thymidine phosphorylase inhibitors: Future anti-tumor drugs
Shahzad, S. A., Yar, M., Khan, Z. A., Shahzadi, L., Naqvi, S. A. R., Mahmood, A., Ullah, S., Shaikh, A. J., Sherazi, T. A., Bale, A. T., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.01.005 · Cited by 73
Paluri, R. K., Li, P., Anderson, A., Nandagopal, L., McArdle, T., Young, M., Robert, F., Naik, G., & Saleh, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-64906-4 · Cited by 75
Jensen, L. H., Rogatto, S. R., Lindebjerg, J., Havelund, B. M., Abildgaard, C., do Canto, L. M., Vagn-Hansen, C., Dam, C., Rafaelsen, S. R., & Hansen, T. F. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02683-4 · Cited by 77
Skårderud, M. R., Dyhl-Polk, A., Vistisen, K. K., Larsen, F. O., & Nielsen, D. L. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.011 · Cited by 77
Fluoropyrimidine-induced cardiotoxicity
Depetris, I., Marino, D., Bonzano, A., Cagnazzo, C., Filippi, R., Aglietta, M., & Leone, F. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.02.002 · Cited by 71
The Evolving Treatment Landscape in BRAF-V600E–Mutated Metastatic Colorectal Cancer
Tabernero, J., Ros, J., & Élez, E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349561 · Cited by 59
Self-citationGupta, R., Meric‐Bernstam, F., Rothe, M., Garrett-Mayer, E. S., Mangat, P. K., D’Andre, S. D., Ahn, E. R., O'Lone, R., Halabi, S., Grantham, G. N., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00306 · Cited by 90
Thymidine catabolism as a metabolic strategy for cancer survival
Tabata, S., Yamamoto, M., Goto, H., Hirayama, A., Ohishi, M., Kuramoto, T., Mitsuhashi, A., Ikeda, R., Haraguchi, M., Kawahara, K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.061 · Cited by 68
Kreidieh, M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · BioMed Research International · doi:10.1155/2020/9037217 · Cited by 80
Parseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3138 · Cited by 67
Pishvaian, M. J., Slack, R. S., Jiang, W., He, A. R., Hwang, J. J., Hankin, A., Dorsch‐Vogel, K., Kukadiya, D., Weiner, L. M., Marshall, J. L., et al. (2018) · Cancer · doi:10.1002/cncr.31309 · Cited by 69
Van Cutsem, E., Yoshino, T., Lenz, H. J., Lonardi, S., Falcone, A., Limón, M. L., Saunders, M., Sobrero, A., Park, Y. S., Ferreiro, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy241 · Cited by 63
Self-citationYoshino, T., Cleary, J. M., Cutsem, E. V., Mayer, R. J., Ohtsu, A., Shinozaki, E., Falcone, A., Yamazaki, K., Nishina, T., García‐Carbonero, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.005 · Cited by 68
Self-citationThymidine phosphorylase: A potential new target for treating cardiovascular disease
Li, W., & Yue, H. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.10.003 · Cited by 73
Ciardiello, D., Martinelli, E., Troiani, T., Mauri, G., Rossini, D., Martini, G., Napolitano, S., Famiglietti, V., Tufo, S. D., Masi, G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.5635 · Cited by 69
CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure
Tsunekuni, K., Konno, M., Haraguchi, N., Koseki, J., Asai, A., Matsuoka, K., Kobunai, T., Takechi, T., Doki, Y., Mori, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50968-6 · Cited by 64
Naples Prognostic Score Is a Useful Prognostic Marker in Patients With Metastatic Colorectal Cancer
Miyamoto, Y., Hiyoshi, Y., Daitoku, N., Okadome, K., Sakamoto, Y., Yamashita, K., Kuroda, D., Sawayama, H., Iwatsuki, M., Baba, Y., et al. (2019) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001484 · Cited by 63
Kim, J. H., Kim, S. Y., Baek, J. Y., Jun, Y., Ahn, J. B., Kim, H. S., Lee, K., Kim, J., Kim, T., Chang, W. J., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.218 · Cited by 84
Oral drugs in the treatment of metastatic colorectal cancer
Alfonso, P. G., Martín, A. J. M., Morán, L. O., Alsar, J. S., Pérez-Solero, G. T., Codesido, M. B., Ferrandiz, P. A. C., & Cicala, S. G. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211009001 · Cited by 65
Cercek, A., Boucher, T. M., Gluskin, J. S., Aguiló, A., Chou, J. F., Connell, L. C., Capanu, M., Reidy‐Lagunes, D. L., D'Angelica, M. I., & Kemeny, N. E. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24399 · Cited by 64
Cremolini, C., Rossini, D., Martinelli, E., Pietrantonio, F., Lonardi, S., Noventa, S., Tamburini, E., Frassineti, G. L., Mosconi, S., Nichetti, F., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0573 · Cited by 62
Self-citationSEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
Gómez‐España, M. A., Gallego-Plazas, J., González‐Flores, E., Maurel, J., Páez, D., Sastre, J., Aparicio, J., Benavides, M., Feliú, J., & Vera, R. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02002-w · Cited by 71
Satake, H., Kato, T., Oba, K., Kotaka, M., Kagawa, Y., Yasui, H., Nakamura, M., Watanabe, T., Matsumoto, T., Kii, T., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0643 · Cited by 64
Self-citationCutsem, E. V., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne‐Jones, R., Punt, C. J. A., van de Wouw, A. J., Fedyanin, M. Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.024 · Cited by 62
Self-citationUpdate in version 2021 of CSCO guidelines for colorectal cancer from version 2020
Dong, C., Ding, Y., Weng, S., Li, G., Huang, Y., Hu, H., Zhang, Z., Zhang, S., & Yuan, Y. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.03.02 · Cited by 65
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Chen, M., Bie, L., & Ying, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115514 · Cited by 60
Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma
Tanaka, T., Kaneko, M., Nozawa, H., Emoto, S., Murono, K., Otani, K., Sasaki, K., Nishikawa, T., Kiyomatsu, T., Hata, K., et al. (2017) · Neuroendocrinology · doi:10.1159/000478743 · Cited by 63
Multiple treatment lines and prognosis in metastatic colorectal cancer patients
Carlomagno, C., Stefano, A. D., Rosanova, M., Falco, S. D., Attademo, L., Fiore, G., & Placido, S. D. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9748-7 · Cited by 62
Tabernero, J. M., Argilés, G., Sobrero, A. F., Borg, C., Ohtsu, A., Mayer, R. J., Vidot, L., Vera, S. R. M., & Cutsem, E. V. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000752 · Cited by 59
Self-citationPrecision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 71
Oral versus intravenous fluoropyrimidines for colorectal cancer
Chionh, F. J. M., Lau, D., Yeung, Y. H., Price, T. J., & Tebbutt, N. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008398.pub2 · Cited by 65
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102
Hamauchi, S., Yamazaki, K., Masuishi, T., Kito, Y., Komori, A., Tsushima, T., Narita, Y., Todaka, A., Ishihara, M., Yokota, T., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.005 · Cited by 64
Self-citationCalegari, M. A., Inno, A., Monterisi, S., Orlandi, A., Santini, D., Basso, M., Cassano, A., Martini, M., Cenci, T., Pascalis, I. D., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.109 · Cited by 55
Colorectal cancer in adolescents and young adults: Defining a growing threat
Levine, O. H., & Zbuk, K. M. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27941 · Cited by 61
Curcumin: A therapeutic strategy for colorectal cancer?
de Porras, V. R., Layos, L., & Martinez‐Balibrea, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.004 · Cited by 61
Bianchi, A. S., Loupakis, F., Argilés, G., & Prager, G. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw191 · Cited by 58
Lee, J. J., & Chu, E. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.06.004 · Cited by 58
Targeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 55
Self-citationLee, V., Wang, J., ZAHURAK, M. L., Gootjes, E. C., Verheul, H. M. W., Parkinson, R. M., Kerner, Z. J., Sharma, A. R., Rosner, G. L., Jesus‐Acosta, A. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0421 · Cited by 56
Johnson, B., Haymaker, C., Parra, E. R., Soto, L. M. S., Wang, X., Thomas, J. V., Dasari, A. N., Morris, V. K., Raghav, K. P. S., Vilar, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005332 · Cited by 59
Gharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 65
Precision treatment in colorectal cancer: Now and the future
Yau, T. O. (2019) · JGH Open · doi:10.1002/jgh3.12153 · Cited by 61
Marcus, L. J., Lemery, S. J., Khasar, S. G., Wearne, E., Helms, W. S., Yuan, W., He, K., Cao, X., Yu, J., Zhao, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2157 · Cited by 55
Li, J., Cong, L., Liu, J., Peng, L., Wang, J., Feng, A., Yue, J., Li, L., Wang, X., & Wang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594125 · Cited by 54
Pietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02026 · Cited by 51
Salvatore, L., Aprile, G., Arnoldi, E., Aschele, C., Carnaghi, C., Cosimelli, M., Maiello, E., Normanno, N., Sciallero, S., Valvo, F., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000147 · Cited by 54
Promising New Agents for Colorectal Cancer
Das, S., Ciombor, K. K., Haraldsdóttir, S., & Goldberg, R. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0543-z · Cited by 56
HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer
Cuyper, A. D., den Eynde, M. V., & Machiels, J. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.007 · Cited by 55
Rimassa, L., Bozzarelli, S., Pietrantonio, F., Cordio, S., Lonardi, S., Toppo, L., Zaniboni, A., Bordonaro, R., Di Bartolomeo, M., Tomasello, G., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.004 · Cited by 50
Self-citationTabernero, J., Taieb, J., Prager, G. W., Ciardiello, F., Fakih, M., Leger, C., Fougeray, R., Amellal, N., & van Cutsem, E. (2021) · Future Oncology · doi:10.2217/fon-2020-1238 · Cited by 46
Self-citationTargeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Ros, J., Vaghi, C., Baraibar, I., Gonzalez, N. S., Rodríguez-Castells, M., García, A., Alcaráz, A., Salvà, F., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063304 · Cited by 62
Self-citationPietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw627 · Cited by 53
Self-citationMasuishi, T., Tsuji, A., Kotaka, M., Nakamura, M., Kochi, M., Takagane, A., Shimada, K., Denda, T., Segawa, Y., Tanioka, H., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01042-w · Cited by 53
Dasari, A. N., Sobrero, A. F., Yao, J. C., Yoshino, T., Schelman, W. R., Yang, Z., Chien, C., Kania, M. K., Tabernero, J. M., & Eng, C. (2021) · Future Oncology · doi:10.2217/fon-2021-0202 · Cited by 56
Self-citationBando, H., Doi, T., Muro, K., Yasui, H., Nishina, T., Yamaguchi, K., Takahashi, S., Nomura, S., Kuno, H., Shitara, K., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.009 · Cited by 49
Self-citationSecond-line systemic therapy for metastatic colorectal cancer
Mocellin, S., Baretta, Z., Figuls, M. R. I., Solà, I., Martín-Richard, M., Hallum, S., & Bonfill, X. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006875.pub3 · Cited by 50
Emergence of TNIK inhibitors in cancer therapeutics
Yamada, T., & Masuda, M. (2017) · Cancer Science · doi:10.1111/cas.13203 · Cited by 48
Oh, C. R., Kim, J. E., Hong, Y. S., Kim, S. Y., Ahn, J. B., Baek, J. Y., Lee, M. A., Kang, M. J., Cho, S., Beom, S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33966 · Cited by 51
Patel, M. R., Falchook, G. S., Hamada, K., Makris, L., & Bendell, J. C. (2021) · Cancer Medicine · doi:10.1002/cam4.3630 · Cited by 52
Self-citationJohnson, D., Chee, C. E., Wong, W., Lam, R. C. T., Tan, I. B. H., & Ma, B. B. Y. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102700 · Cited by 53
Thymidine phosphorylase in cancer aggressiveness and chemoresistance
Furukawa, T., Tabata, S., Yamamoto, M., Kawahara, K., Shinsato, Y., Minami, K., Shimokawa, M., & Akiyama, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.019 · Cited by 48
Recent Developments of Systemic Chemotherapy for Gastric Cancer
Arai, H., & Nakajima, T. E. (2020) · Cancers · doi:10.3390/cancers12051100 · Cited by 51
Yu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
Jurczyk, M., Król, M., Midro, A., Kurnik‐Łucka, M., Poniatowski, A., & Gil, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194426 · Cited by 56
Konno, M., Asai, A., Kawamoto, K., Nishida, N., Satoh, T., Doki, Y., Mori, M., & Ishii, H. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3885 · Cited by 49
Kennedy, A. S., Cohn, M., Coldwell, D. M., Drooz, A. T., Ehrenwald, E., Kaiser, A., Nutting, C. W., Rose, S. C., Wang, E. A., & Savin, M. A. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.03.10 · Cited by 48
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1
Herold, N., Rudd, S. G., Sanjiv, K., Kutzner, J., Myrberg, I. H., Paulin, C. B. J., Olsen, T. K., Helleday, T., Henter, J., & Schaller, T. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.05.001 · Cited by 49
Trifluridine/Tipiracil: An Emerging Strategy for the Management of Gastrointestinal Cancers
Peeters, M., Cervantes, A. M. R., Vera, S. R. M., & Taïeb, J. (2018) · Future Oncology · doi:10.2217/fon-2018-0147 · Cited by 62
Self-citationScott, A. J., Arcaroli, J. J., Bagby, S. M., Yahn, R., Huber, K. M., Serkova, N. J., Nguyen, A., Kim, J., Thorburn, A., Vogel, J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0131 · Cited by 48
Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
Jacome, A. A. D. A., & Eng, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1680636 · Cited by 48
Kotani, D., Kuboki, Y., Horasawa, S., Kaneko, A., Nakamura, Y., Kawazoe, A., Bando, H., Taniguchi, H., Shitara, K., Kojima, T., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6475-6 · Cited by 48
Self-citationSuenaga, M., Mashima, T., Kawata, N., Wakatsuki, T., Horiike, Y., Matsusaka, S., Dan, S., Shinozaki, E., Seimiya, H., Mizunuma, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9187 · Cited by 49
Self-citation
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.